This study aimed to establish the quantitative relationship between metabolisable energy intake (MEI) and growth performance, carcass tissue composition and internal fat, taking into consideration animal precocity, maturity and tail nature. Data from 67 publications were used in the meta-analysis. Diets were characterized and three classes were identified (low medium and high energy density diets). Breeds were characterized according to tail nature, precocity and maturity stage. Average daily gain (ADG) responded to MEI in all animals weighing less than 60% of their adult weight regardless their precocity or their tail nature. At the same level of MEI, the higher the diet energy density, the higher the ADG. In animals weighing less than 42% of adult weight and receiving a high starch diet, carcass muscle and internal fat responded to MEI. Whereas, for animals that weighed between 43% and 75% of adult weight, increases in MEI influenced carcass adipose tissue.

Effects of metabolizable energy intake on post weaning lamb growth performance, carcass tissue composition and internal fat depend on animal characteristics: A meta-analysis.

Chronic gastritis (CG) is an inflammatory disease of the gastric mucosa. Shen-ling-bai-zhu san (SLBZS), a traditional Chinese medicine formula, is widely used for treating CG. Nevertheless, its effects are currently unclear.
To determine the clinical evidence and potential mechanisms of SLBZS for the treatment of CG.
We systematically searched 3 English (PubMed, Embase, Medline) and 4 Chinese databases (Cochrane Library Central Register of Controlled Trials, China National Knowledge Infrastructure database, Wanfang Data Knowledge Service Platform, and the VIP information resource integration service platform) without language or publication bias restriction. Qualified studies were selected according to pre-set inclusion and exclusion criteria. RevMan 5.3 software was used for meta-analysis and literature quality assessment, Stata 14.0 software was used for sensitivity analysis, GRADE profiler 3.6 was used to evaluate the quality of evidence. And then, network pharmacology analysis was applied to primary research the mechanisms of action of SLBZS on CG.
Fourteen studies were finally included, covering 1335 participants. Meta-analysis indicated that: (1) SLBZS was superior to conventional therapies [risk ratio (RR): 1.29, 95% confidence interval (CI): 1.21 to 1.37, 
SLBZS might be useful in treating CG, but long-term effects and specific clinical mechanisms of it maintain unclear. More samples and high-quality clinical experiments should be assessed and verified in the next step.

Papers